
BlossomHill Therapeutics, Inc. (NASDAQ:BLSM – Free Report) – Research analysts at HC Wainwright dropped their FY2026 EPS estimates for shares of BlossomHill Therapeutics in a research report issued on Monday, November 16th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($5.27) for the year, down from their prior forecast of ($4.75). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for BlossomHill Therapeutics’ current full-year earnings is ($5.54) per share. HC Wainwright also issued estimates for BlossomHill Therapeutics’ Q4 2026 earnings at ($0.90) EPS.
BLSM has been the topic of a number of other reports. Weiss Ratings began coverage on shares of BlossomHill Therapeutics in a research note on Tuesday, November 3rd. They set a “sell (e-)” rating on the stock. Leerink Partners raised their price objective on shares of BlossomHill Therapeutics from $36.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, September 21st. JPMorgan Chase & Co. began coverage on shares of BlossomHill Therapeutics in a report on Tuesday, September 1st. They set an “overweight” rating and a $28.00 price objective on the stock. Lifesci Capital began coverage on shares of BlossomHill Therapeutics in a research report on Tuesday, September 1st. They set an “outperform” rating and a $32.00 target price on the stock. Finally, Guggenheim lifted their price target on shares of BlossomHill Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, September 21st. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, BlossomHill Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $35.00.
BlossomHill Therapeutics Trading Up 10.8%
BlossomHill Therapeutics stock opened at $15.13 on Wednesday. BlossomHill Therapeutics has a 1-year low of $11.02 and a 1-year high of $27.99. The company has a 50 day simple moving average of $17.68.
BlossomHill Therapeutics (NASDAQ:BLSM – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.93) by ($0.36).
About BlossomHill Therapeutics
BlossomHill Therapeutics is a biotechnology company focused on developing medicines for cancer. Its research has centered on targeted small-molecule treatments designed to address cancer-related genetic changes. The company’s pipeline has included BH-306, an investigational inhibitor of mutant IDH1 being developed for cancers associated with that mutation. The program is in development and is not a marketed treatment. Publicly available information about the company’s leadership and geographic operations is limited.
Recommended Stories
- Five stocks we like better than BlossomHill Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
